Show Summary Details
Page of

Intracranial tumours 

Intracranial tumours
Intracranial tumours

Jeremy Rees



Pathogenesis—importance of IDH1 mutations as new markers of favourable prognosis.

Treatment—(1) brain metastases—focal treatments (e.g. neurosurgery or stereotactic radiosurgery) for patients with 1 to 3 metastases and good performance status; (2) technological advances—use of ‘cyberknife’ radiotherapy; (3) chemotherapy—use of temozolomide in combination with radiotherapy.

Updated on 28 November 2012. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 July 2018

Intracranial tumours represent about 2% of all cancers. There are no known risk factors apart from prior irradiation to the skull and brain and a few rare neurogenetic syndromes, e.g. neurofibromatosis, von Hippel–Lindau syndrome, Li–Fraumeni syndrome. They may be intrinsic or extrinsic, which determines potential resectability. Neuroepithelial tumours (predominantly gliomas) account for 50 to 60% of all primary tumours. Recent discovery of ...

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.